May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Management of Severe Hypotony With Intravitreal Injection of Healon GV
G. Tosi; W. Schiff; G. Barile; N. Yoshida; S. Chang
Author Affiliations & Notes
  • G. Tosi
    Dept of Ophthalmology, University of Siena, Siena, Italy
    Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University, New York, New York, USA, Columbia University, New York, New York, USA, NY
  • W. Schiff
    Dept of Ophthalmology, Columbia University, New York, NY
  • G. Barile
    Dept of Ophthalmology, Columbia University, New York, NY
  • N. Yoshida
    Dept of Ophthalmology, Columbia University, New York, NY
  • S. Chang
    Dept of Ophthalmology, Columbia University, New York, NY
  • Footnotes
    Commercial Relationships  G. Tosi, None; W. Schiff, None; G. Barile, None; N. Yoshida, None; S. Chang, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5493. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Management of Severe Hypotony With Intravitreal Injection of Healon GV
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      G. Tosi, W. Schiff, G. Barile, N. Yoshida, S. Chang; Management of Severe Hypotony With Intravitreal Injection of Healon GV . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5493.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: To investigate the effect of intravitreal injection of Healon GV® (sodium hyaluronate 1.4%) in the management of severe hypotony. Methods: 0.3 ml of Healon GV was injected intravitreally to treat unresponsive hypotony (1–2 mmHg) following successful repair of longstanding retinal detachment in three patients and following chronic uveitis in one patient. Results: Patients were followed up for 2, 3, 8 and 16 months, respectively. IOP returned within normal range in two patients (14 and 10 mmHg, respectively) and increased from 1 to 5 mmHg in the other two. All patients experienced an improvement in VA, ocular discomfort and ocular findings. No complications were observed. Conclusions: In the four patients here analyzed, intravitreal injection of Healon GV was helpful in reducing the structural and functional changes induced by severe hypotony. A more numerous case series, studied prospectively, is needed before drawing definitive conclusions.

Keywords: intraocular pressure • retinal detachment • proliferative vitreoretinopathy 
© 2005, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept